-
1
-
-
55849133043
-
Diabetes-related microvascular and macrovascular diseases in the physical therapy setting
-
PID: 18801863
-
Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88(11):1322–35.
-
(2008)
Phys Ther
, vol.88
, Issue.11
, pp. 1322-1335
-
-
Cade, W.T.1
-
2
-
-
84892649479
-
Standards of medical care in diabetes—2014
-
American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl 1):S14–80.
-
(2014)
Diabetes Care
, vol.37
, pp. S14-S80
-
-
American Diabetes Association1
-
3
-
-
84986216476
-
-
International Diabetes Federation. Treatment algorithm for people with type 2 diabetes. Available from. Accessed Feb 3, 2016
-
International Diabetes Federation. Treatment algorithm for people with type 2 diabetes. Available from https://www.idf.org/treatment-algorithm-people-type-2-diabetes. Accessed Feb 3, 2016.
-
-
-
-
4
-
-
84986212165
-
-
American Diabetes Association. Diabetes Management Guidelines. 2015. Available from:. Accessed Feb 3, 2016
-
American Diabetes Association. Diabetes Management Guidelines. 2015. Available from: http://www.ndei.org/ADA-diabetes-management-guidelines-pharmacologic-therapy-for-type-2-diabetes.aspx. Accessed Feb 3, 2016.
-
-
-
-
5
-
-
84986190212
-
-
AACE/ACE Comprehensive Diabetes Management Algorithm. 2015. Available from:. Accessed Feb 3, 2016
-
AACE/ACE Comprehensive Diabetes Management Algorithm. 2015. Available from: https://www.aace.com/files/aace_algorithm.pdf. Accessed Feb 3, 2016.
-
-
-
-
6
-
-
84986229137
-
-
National Institute for Health and Care Excellence. Algorithm for blood glucose lowering therapy in adults with type 2 diabetes. Available from:. Accessed Feb 3, 2016
-
National Institute for Health and Care Excellence. Algorithm for blood glucose lowering therapy in adults with type 2 diabetes. Available from: http://www.nice.org.uk/guidance/ng28/resources/algorithm-for-blood-glucose-lowering-therapy-in-adults-with-type-2-diabetes-2185604173. Accessed Feb 3, 2016.
-
-
-
-
7
-
-
84919999219
-
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
PID: 25538310
-
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.
-
(2015)
Diabetes Care
, vol.38
, Issue.1
, pp. 140-149
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
Diamant, M.4
Ferrannini, E.5
Nauck, M.6
-
8
-
-
0027248866
-
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
-
COI: 1:STN:280:DyaK2c%2FgvF2qtQ%3D%3D, PID: 8405741
-
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–4.
-
(1993)
Diabetologia
, vol.36
, Issue.8
, pp. 741-744
-
-
Nauck, M.A.1
Kleine, N.2
Orskov, C.3
Holst, J.J.4
Willms, B.5
Creutzfeldt, W.6
-
9
-
-
33847617011
-
Mechanisms of Action of GLP-1 in the Pancreas
-
COI: 1:CAS:528:DC%2BD2sXislKjsb4%3D, PID: 17306374
-
Doyle ME, Egan JM. Mechanisms of Action of GLP-1 in the Pancreas. Pharmacol Ther. 2007;113(3):546–93.
-
(2007)
Pharmacol Ther
, vol.113
, Issue.3
, pp. 546-593
-
-
Doyle, M.E.1
Egan, J.M.2
-
10
-
-
84986205440
-
-
Novo Nordisk. Novo Nordisk Annual Report 2015. Available from:. Accessed Feb 3, 2016
-
Novo Nordisk. Novo Nordisk Annual Report 2015. Available from: http://www.novonordisk.com/content/dam/Denmark/HQ/Commons/documents/Novo-Nordisk-Annual-Report-2015.PDF. Accessed Feb 3, 2016.
-
-
-
-
11
-
-
62449129181
-
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
-
COI: 1:CAS:528:DC%2BD1MXkvVGqur8%3D, PID: 19317822
-
Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–78.
-
(2009)
Diabet Med
, vol.26
, Issue.3
, pp. 268-278
-
-
Marre, M.1
Shaw, J.2
Brandle, M.3
Bebakar, W.M.4
Kamaruddin, N.A.5
Strand, J.6
-
12
-
-
62449169287
-
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study
-
COI: 1:CAS:528:DC%2BD1MXhs1Ggu7g%3D, PID: 18931095
-
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.
-
(2009)
Diabetes Care
, vol.32
, Issue.1
, pp. 84-90
-
-
Nauck, M.1
Frid, A.2
Hermansen, K.3
Shah, N.S.4
Tankova, T.5
Mitha, I.H.6
-
13
-
-
59449101432
-
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
-
COI: 1:CAS:528:DC%2BD1MXhsFKgur0%3D, PID: 18819705
-
Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–81.
-
(2009)
Lancet
, vol.373
, Issue.9662
, pp. 473-481
-
-
Garber, A.1
Henry, R.2
Ratner, R.3
Garcia-Hernandez, P.A.4
Rodriguez-Pattzi, H.5
Olvera-Alvarez, I.6
-
14
-
-
67650066860
-
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD)
-
COI: 1:CAS:528:DC%2BD1MXps1KqsLs%3D, PID: 19289857
-
Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32(7):1224–30.
-
(2009)
Diabetes Care
, vol.32
, Issue.7
, pp. 1224-1230
-
-
Zinman, B.1
Gerich, J.2
Buse, J.B.3
Lewin, A.4
Schwartz, S.5
Raskin, P.6
-
15
-
-
69949117621
-
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial
-
COI: 1:CAS:528:DC%2BD1MXhtVygtLnE, PID: 19688338
-
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–55.
-
(2009)
Diabetologia
, vol.52
, Issue.10
, pp. 2046-2055
-
-
Russell-Jones, D.1
Vaag, A.2
Schmitz, O.3
Sethi, B.K.4
Lalic, N.5
Antic, S.6
-
16
-
-
67649666737
-
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
-
COI: 1:CAS:528:DC%2BD1MXotFCgtb4%3D, PID: 19515413
-
Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.
-
(2009)
Lancet
, vol.374
, Issue.9683
, pp. 39-47
-
-
Buse, J.B.1
Rosenstock, J.2
Sesti, G.3
Schmidt, W.E.4
Montanya, E.5
Brett, J.H.6
-
18
-
-
84899585635
-
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
-
COI: 1:CAS:528:DC%2BC2cXosFSktro%3D, PID: 24703047
-
Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2(4):289–97.
-
(2014)
Lancet Diabetes Endocrinol.
, vol.2
, Issue.4
, pp. 289-297
-
-
Pratley, R.E.1
Nauck, M.A.2
Barnett, A.H.3
Feinglos, M.N.4
Ovalle, F.5
Harman-Boehm, I.6
-
19
-
-
84908177336
-
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
-
COI: 1:CAS:528:DC%2BC2cXhtFGmtLnI, PID: 25018121
-
Dungan KM, Povedano ST, Forst T, González JGG, Atisso C, Sealls W, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349–57.
-
(2014)
Lancet
, vol.384
, Issue.9951
, pp. 1349-1357
-
-
Dungan, K.M.1
Povedano, S.T.2
Forst, T.3
González, J.G.G.4
Atisso, C.5
Sealls, W.6
-
20
-
-
84872084453
-
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
-
COI: 1:CAS:528:DC%2BC38Xhs1CjsbvM, PID: 23141817
-
Buse JB, Nauck M, Forst T, Sheu WHH, Shenouda SK, Heilmann CR, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–24.
-
(2013)
Lancet
, vol.381
, Issue.9861
, pp. 117-124
-
-
Buse, J.B.1
Nauck, M.2
Forst, T.3
Sheu, W.H.H.4
Shenouda, S.K.5
Heilmann, C.R.6
-
21
-
-
77952309372
-
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
-
COI: 1:CAS:528:DC%2BC3cXltFOmsLo%3D, PID: 20417856
-
Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–56.
-
(2010)
Lancet
, vol.375
, Issue.9724
, pp. 1447-1456
-
-
Pratley, R.E.1
Nauck, M.2
Bailey, T.3
Montanya, E.4
Cuddihy, R.5
Filetti, S.6
-
22
-
-
79952755181
-
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
-
COI: 1:CAS:528:DC%2BC3MXktFeht7Y%3D, PID: 21355967
-
Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407.
-
(2011)
Int J Clin Pract
, vol.65
, Issue.4
, pp. 397-407
-
-
Pratley, R.1
Nauck, M.2
Bailey, T.3
Montanya, E.4
Cuddihy, R.5
Filetti, S.6
-
23
-
-
84866650686
-
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial
-
COI: 1:CAS:528:DC%2BC38Xhs1Gks77F, PID: 22851600
-
Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986–93.
-
(2012)
Diabetes Care
, vol.35
, Issue.10
, pp. 1986-1993
-
-
Pratley, R.E.1
Nauck, M.A.2
Bailey, T.3
Montanya, E.4
Filetti, S.5
Garber, A.J.6
-
24
-
-
84961295369
-
Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: a randomized, 52-week, open-label, parallel-group trial
-
COI: 1:CAS:528:DC%2BC28XjvFGnsg%3D%3D, PID: 26816604
-
Kaku K, Kiyosue A, Ono Y, Shiraiwa T, Kaneko S, Nishijima K, et al. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: a randomized, 52-week, open-label, parallel-group trial. J Diabetes Investig. 2016;7(1):76–84.
-
(2016)
J Diabetes Investig.
, vol.7
, Issue.1
, pp. 76-84
-
-
Kaku, K.1
Kiyosue, A.2
Ono, Y.3
Shiraiwa, T.4
Kaneko, S.5
Nishijima, K.6
-
25
-
-
84977567493
-
-
J Diabetes Investig: Epub ahead of print)
-
Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, Nishijima K, et al. Combination therapy with liraglutide and insulin in Japanese subjects with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial. J Diabetes Investig. 2016. (Epub ahead of print).
-
(2016)
Combination therapy with liraglutide and insulin in Japanese subjects with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial
-
-
Seino, Y.1
Kaneko, S.2
Fukuda, S.3
Osonoi, T.4
Shiraiwa, T.5
Nishijima, K.6
-
26
-
-
84986236923
-
-
National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. Accessed Feb 3, 2016
-
National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. Available at: https://www.nice.org.uk/article/pmg9/chapter/foreword. Accessed Feb 3, 2016.
-
-
-
-
28
-
-
84936928911
-
Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study
-
COI: 1:CAS:528:DC%2BC2MXlvVGlurw%3D, PID: 25832470
-
Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015;32(4):341–55.
-
(2015)
Adv Ther.
, vol.32
, Issue.4
, pp. 341-355
-
-
Buysman, E.K.1
Liu, F.2
Hammer, M.3
Langer, J.4
-
29
-
-
84937513173
-
ROOTS: a multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza) in type 2 diabetic patients
-
PID: 26004030
-
Buysschaert M, D’Hooge D, Preumont V, Roots Study Group. ROOTS: a multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza) in type 2 diabetic patients. Diabetes Metab Syndr. 2015;9(3):139–42.
-
(2015)
Diabetes Metab Syndr
, vol.9
, Issue.3
, pp. 139-142
-
-
Buysschaert, M.1
D’Hooge, D.2
Preumont, V.3
Roots Study Group4
-
30
-
-
84982732820
-
Add-on treatment with liraglutide improves glycemic control in patients with type 2 diabetes on metformin therapy
-
COI: 1:CAS:528:DC%2BC2MXhtV2murnF, PID: 25844858
-
Chiefari E, Capula C, Vero A, Oliverio R, Puccio L, Liguori R, et al. Add-on treatment with liraglutide improves glycemic control in patients with type 2 diabetes on metformin therapy. Diabetes Technol Ther. 2015;17(7):468–74.
-
(2015)
Diabetes Technol Ther.
, vol.17
, Issue.7
, pp. 468-474
-
-
Chiefari, E.1
Capula, C.2
Vero, A.3
Oliverio, R.4
Puccio, L.5
Liguori, R.6
-
31
-
-
84925630817
-
Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation
-
COI: 1:STN:280:DC%2BC2M7htV2ktg%3D%3D, PID: 25218924
-
Cotugno M, Nosso G, Saldalamacchia G, Vitagliano G, Griffo E, Lupoli R, et al. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation. Acta Diabetol. 2015;52(2):331–6.
-
(2015)
Acta Diabetol
, vol.52
, Issue.2
, pp. 331-336
-
-
Cotugno, M.1
Nosso, G.2
Saldalamacchia, G.3
Vitagliano, G.4
Griffo, E.5
Lupoli, R.6
-
32
-
-
84888630523
-
A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice
-
PID: 23225378
-
Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther. 2013;4(1):27–40.
-
(2013)
Diabetes Ther.
, vol.4
, Issue.1
, pp. 27-40
-
-
Evans, M.1
McEwan, P.2
O’Shea, R.3
George, L.4
-
33
-
-
84907353296
-
Efficacité en pratique clinique courante des incrétino-mimétiques dans le traitement du diabète de type 2: résultats d’une enquête nationale rétrospective au Royaume-Uni
-
Evans M, McEwan P, O’Shea R, George L. Efficacité en pratique clinique courante des incrétino-mimétiques dans le traitement du diabète de type 2: résultats d’une enquête nationale rétrospective au Royaume-Uni. Méd Mal Métab. 2014;8(2):177–83.
-
(2014)
Méd Mal Métab.
, vol.8
, Issue.2
, pp. 177-183
-
-
Evans, M.1
McEwan, P.2
O’Shea, R.3
George, L.4
-
34
-
-
84890571759
-
Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients
-
COI: 1:CAS:528:DC%2BC3sXhvVKhurbN, PID: 23754673
-
Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, et al. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol. 2013;50(6):943–9.
-
(2013)
Acta Diabetol
, vol.50
, Issue.6
, pp. 943-949
-
-
Fadini, G.P.1
Simioni, N.2
Frison, V.3
Dal Pos, M.4
Bettio, M.5
Rocchini, P.6
-
35
-
-
84893813443
-
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
-
COI: 1:CAS:528:DC%2BC2cXitFKktLg%3D, PID: 24199745
-
Funch D, Gydesen H, Tornoe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab. 2014;16(3):273–5.
-
(2014)
Diabetes Obes Metab
, vol.16
, Issue.3
, pp. 273-275
-
-
Funch, D.1
Gydesen, H.2
Tornoe, K.3
Major-Pedersen, A.4
Chan, K.A.5
-
36
-
-
84944074514
-
Effectiveness and persistence with liraglutide among patients with type 2 diabetes in routine clinical practice–EVIDENCE: a prospective, 2-year follow-up, observational, post-marketing study
-
COI: 1:CAS:528:DC%2BC2MXhs1Shtb%2FP, PID: 26424330
-
Gautier JF, Martinez L, Penfornis A, Eschwege E, Charpentier G, Huret B, et al. Effectiveness and persistence with liraglutide among patients with type 2 diabetes in routine clinical practice–EVIDENCE: a prospective, 2-year follow-up, observational, post-marketing study. Adv Ther. 2015;32(9):838–53.
-
(2015)
Adv Ther.
, vol.32
, Issue.9
, pp. 838-853
-
-
Gautier, J.F.1
Martinez, L.2
Penfornis, A.3
Eschwege, E.4
Charpentier, G.5
Huret, B.6
-
37
-
-
84942809131
-
Effectiveness of liraglutide in type II diabetes mellitus management: experience in emirati patients
-
PID: 26441485
-
Ghuman NK, Saadah LM, Al Najjar MS, Shaheen DY, Am SI, Al Ali MM. Effectiveness of liraglutide in type II diabetes mellitus management: experience in emirati patients. Clin Med Insights Endocrinol Diabetes. 2015;8:67–72.
-
(2015)
Clin Med Insights Endocrinol Diabetes
, vol.8
, pp. 67-72
-
-
Ghuman, N.K.1
Saadah, L.M.2
Al Najjar, M.S.3
Shaheen, D.Y.4
Am, S.I.5
Al Ali, M.M.6
-
38
-
-
84907429444
-
Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study
-
PID: 25237400
-
Inoue K, Maeda N, Fujishima Y, Fukuda S, Nagao H, Yamaoka M, et al. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol Metab Syndr. 2014;6(1):95.
-
(2014)
Diabetol Metab Syndr.
, vol.6
, Issue.1
, pp. 95
-
-
Inoue, K.1
Maeda, N.2
Fujishima, Y.3
Fukuda, S.4
Nagao, H.5
Yamaoka, M.6
-
39
-
-
84926163580
-
Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy
-
PID: 25626486
-
Lapolla A, Frison V, Bettio M, Dal Pos M, Rocchini P, Panebianco G, et al. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. Clin Ther. 2015;37(3):574–84.
-
(2015)
Clin Ther
, vol.37
, Issue.3
, pp. 574-584
-
-
Lapolla, A.1
Frison, V.2
Bettio, M.3
Dal Pos, M.4
Rocchini, P.5
Panebianco, G.6
-
40
-
-
84866181193
-
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone
-
PID: 22927782
-
Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal. 2012;2012:496453.
-
(2012)
ScientificWorldJournal.
, vol.2012
, pp. 496453
-
-
Ohki, T.1
Isogawa, A.2
Iwamoto, M.3
Ohsugi, M.4
Yoshida, H.5
Toda, N.6
-
41
-
-
84884323872
-
Vliv inkretinového mimetika liraglutidu (Victoza) na hmotnost a hladiny glykovaného hemoglobinu u nemocných s diabetes mellitus 2. typu v diabetologických ordinacích ČR–studie BIVI
-
Perušičová J, Skupina, Pithová a pracovní P. Vliv inkretinového mimetika liraglutidu (Victoza) na hmotnost a hladiny glykovaného hemoglobinu u nemocných s diabetes mellitus 2. typu v diabetologických ordinacích ČR–studie BIVI. Interní medicína pro praxi. 2013;15(5):170–5.
-
(2013)
Interní medicína pro praxi
, vol.15
, Issue.5
, pp. 170-175
-
-
Perušičová, J.1
Skupina2
Pithová a pracovní, P.3
-
42
-
-
84876571220
-
Long-term effectiveness and safety of liraglutide in clinical practice
-
COI: 1:STN:280:DC%2BC3svgvFyktg%3D%3D
-
Ponzani P. Long-term effectiveness and safety of liraglutide in clinical practice. Miner Endocrinol. 2013;38(1):103–12.
-
(2013)
Miner Endocrinol
, vol.38
, Issue.1
, pp. 103-112
-
-
Ponzani, P.1
-
43
-
-
84946034087
-
Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study
-
COI: 1:CAS:528:DC%2BC28XhvFSisLw%3D, PID: 26328783
-
Rigato M, Avogaro A, Fadini GP. Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study. J Endocrinol Invest. 2015;38(12):1357–63.
-
(2015)
J Endocrinol Invest
, vol.38
, Issue.12
, pp. 1357-1363
-
-
Rigato, M.1
Avogaro, A.2
Fadini, G.P.3
-
44
-
-
84923887216
-
Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients
-
COI: 1:CAS:528:DC%2BC28XhvFSjsrY%3D, PID: 25173876
-
Russo GT, Labate AM, Giandalia A, Romeo EL, Villari P, Alibrandi A, et al. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest. 2015;38(1):81–9.
-
(2015)
J Endocrinol Invest
, vol.38
, Issue.1
, pp. 81-89
-
-
Russo, G.T.1
Labate, A.M.2
Giandalia, A.3
Romeo, E.L.4
Villari, P.5
Alibrandi, A.6
-
45
-
-
84942192266
-
Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes
-
COI: 1:CAS:528:DC%2BC2MXhtlyjsL%2FL, PID: 26277380
-
Thomsen RW, Baggesen LM, Sogaard M, Pedersen L, Norrelund H, Buhl ES, et al. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes. Diabetologia. 2015;58(10):2247–53.
-
(2015)
Diabetologia
, vol.58
, Issue.10
, pp. 2247-2253
-
-
Thomsen, R.W.1
Baggesen, L.M.2
Sogaard, M.3
Pedersen, L.4
Norrelund, H.5
Buhl, E.S.6
-
46
-
-
84907471769
-
One-year efficacy of liraglutide or bariatric surgery in obese type 2 diabetic patients: a retrospective study
-
Vitagliano G, Nosso G, Cotugno M, Saldalamacchia G, Lupoli R, Griffo E, et al. One-year efficacy of liraglutide or bariatric surgery in obese type 2 diabetic patients: a retrospective study. G Ital Diabetol Metabol. 2014;34(2):58–63.
-
(2014)
G Ital Diabetol Metabol
, vol.34
, Issue.2
, pp. 58-63
-
-
Vitagliano, G.1
Nosso, G.2
Cotugno, M.3
Saldalamacchia, G.4
Lupoli, R.5
Griffo, E.6
-
47
-
-
84949109019
-
One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study
-
COI: 1:CAS:528:DC%2BC2MXmtVaqsw%3D%3D, PID: 25572181
-
Zavattaro M, Caputo M, Sama MT, Mele C, Chasseur L, Marzullo P, et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine. 2015;50(3):620–6.
-
(2015)
Endocrine
, vol.50
, Issue.3
, pp. 620-626
-
-
Zavattaro, M.1
Caputo, M.2
Sama, M.T.3
Mele, C.4
Chasseur, L.5
Marzullo, P.6
-
48
-
-
84939209734
-
Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial
-
PID: 26064864
-
Bashier AM, Hussain AA, Abdelgadir EI, Eltinay AT, Thadani P, Abdalla ME, et al. Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial. J Diabetes Metab Disord. 2015;14:48.
-
(2015)
J Diabetes Metab Disord
, vol.14
, pp. 48
-
-
Bashier, A.M.1
Hussain, A.A.2
Abdelgadir, E.I.3
Eltinay, A.T.4
Thadani, P.5
Abdalla, M.E.6
-
49
-
-
84919839635
-
Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study
-
COI: 1:CAS:528:DC%2BC2cXhs1KgsLrJ, PID: 25245811
-
Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. Adv Ther. 2014;31(9):986–99.
-
(2014)
Adv Ther.
, vol.31
, Issue.9
, pp. 986-999
-
-
Chitnis, A.S.1
Ganz, M.L.2
Benjamin, N.3
Langer, J.4
Hammer, M.5
-
50
-
-
84899128195
-
Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide
-
PID: 24477354
-
DeKoven M, Lee WC, Bouchard J, Massoudi M, Langer J. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Adv Ther. 2014;31(2):202–16.
-
(2014)
Adv Ther.
, vol.31
, Issue.2
, pp. 202-216
-
-
DeKoven, M.1
Lee, W.C.2
Bouchard, J.3
Massoudi, M.4
Langer, J.5
-
51
-
-
84922005537
-
Efficacy of liraglutide in a real-life cohort
-
COI: 1:CAS:528:DC%2BC2cXptVCmtLY%3D, PID: 24664620
-
Heymann A, Maor Y, Goldstein I, Todorova L, Schertz-Sternberg P, Karasik A. Efficacy of liraglutide in a real-life cohort. Diabetes Ther. 2014;5(1):193–206.
-
(2014)
Diabetes Ther.
, vol.5
, Issue.1
, pp. 193-206
-
-
Heymann, A.1
Maor, Y.2
Goldstein, I.3
Todorova, L.4
Schertz-Sternberg, P.5
Karasik, A.6
-
52
-
-
84920735336
-
Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting
-
PID: 25605673
-
Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. Diabetes Metab Syndr. 2015;9(1):30–3.
-
(2015)
Diabetes Metab Syndr.
, vol.9
, Issue.1
, pp. 30-33
-
-
Kesavadev, J.1
Shankar, A.2
Gopalakrishnan, G.3
Jothydev, S.4
-
53
-
-
84867687757
-
Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting
-
COI: 1:CAS:528:DC%2BC38Xmt1ehtb0%3D, PID: 22536087
-
Kesavadev J, Shankar A, Krishnan G, Jothydev S. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. Int J Gen Med. 2012;5:317–22.
-
(2012)
Int J Gen Med.
, vol.5
, pp. 317-322
-
-
Kesavadev, J.1
Shankar, A.2
Krishnan, G.3
Jothydev, S.4
-
54
-
-
84888403047
-
Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3sXhvVOitL3F, PID: 24843711
-
Kondo Y, Satoh S, Nagakura J, Kimura M, Nezu U, Terauchi Y. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. J Diabetes Investig. 2013;4(6):571–5.
-
(2013)
J Diabetes Investig.
, vol.4
, Issue.6
, pp. 571-575
-
-
Kondo, Y.1
Satoh, S.2
Nagakura, J.3
Kimura, M.4
Nezu, U.5
Terauchi, Y.6
-
55
-
-
84948969329
-
Early liraglutide treatment improves beta-cell function in patients with type 2 diabetes: a retrospective cohort study
-
PID: 26249841
-
Kondo Y, Satoh S, Osada UN, Terauchi Y. Early liraglutide treatment improves beta-cell function in patients with type 2 diabetes: a retrospective cohort study. Endocr J. 2015;62(11):971–80.
-
(2015)
Endocr J
, vol.62
, Issue.11
, pp. 971-980
-
-
Kondo, Y.1
Satoh, S.2
Osada, U.N.3
Terauchi, Y.4
-
56
-
-
84919699153
-
Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States
-
COI: 1:CAS:528:DC%2BC2cXhs1Wqs7bM, PID: 25256818
-
Li Q, Chitnis A, Hammer M, Langer J. Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States. Diabetes Ther. 2014;5(2):579–90.
-
(2014)
Diabetes Ther.
, vol.5
, Issue.2
, pp. 579-590
-
-
Li, Q.1
Chitnis, A.2
Hammer, M.3
Langer, J.4
-
57
-
-
84935001656
-
Clinical effects of liraglutide in a real-world setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study
-
COI: 1:CAS:528:DC%2BC2MXhtVOmsbfF, PID: 26055216
-
Mezquita-Raya P, Reyes-Garcia R, Moreno-Perez O, Escalada-San Martin J, Angel Rubio Herrera M, Lopez de la Torre Casares M. Clinical effects of liraglutide in a real-world setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. Diabetes Ther. 2015;6(2):173–85.
-
(2015)
Diabetes Ther
, vol.6
, Issue.2
, pp. 173-185
-
-
Mezquita-Raya, P.1
Reyes-Garcia, R.2
Moreno-Perez, O.3
Escalada-San Martin, J.4
Angel Rubio Herrera, M.5
Lopez de la Torre Casares, M.6
-
58
-
-
84923372349
-
Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care
-
COI: 1:CAS:528:DC%2BC2MXjtFaktL4%3D, PID: 25302822
-
Nyeland ME, Ploug UJ, Richards A, Garcia Alvarez L, Demuth D, Muthutantri A, et al. Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care. Int J Clin Pract. 2015;69(3):281–91.
-
(2015)
Int J Clin Pract
, vol.69
, Issue.3
, pp. 281-291
-
-
Nyeland, M.E.1
Ploug, U.J.2
Richards, A.3
Garcia Alvarez, L.4
Demuth, D.5
Muthutantri, A.6
-
59
-
-
84895762544
-
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
-
PID: 24559258
-
Rizzo MCM, Patti AM, Di Bartolo V, Rizvi AA, Montalto G, Abate N. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014;13:49.
-
(2014)
Cardiovasc Diabetol.
, vol.13
, pp. 49
-
-
Rizzo, M.C.M.1
Patti, A.M.2
Di Bartolo, V.3
Rizvi, A.A.4
Montalto, G.5
Abate, N.6
-
60
-
-
84896117467
-
The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study
-
COI: 1:CAS:528:DC%2BC2cXktlCgtLw%3D, PID: 24246138
-
Thong KY, McDonald TJ, Hattersley AT, Blann AD, Ramtoola S, Duncan C, et al. The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabet Med. 2014;31(4):403–11.
-
(2014)
Diabet Med
, vol.31
, Issue.4
, pp. 403-411
-
-
Thong, K.Y.1
McDonald, T.J.2
Hattersley, A.T.3
Blann, A.D.4
Ramtoola, S.5
Duncan, C.6
-
61
-
-
84920738014
-
Predictors of response to liraglutide in Japanese type 2 diabetes
-
COI: 1:CAS:528:DC%2BC2cXhslGrs73F, PID: 25458335
-
Toyoda M, Yokoyama H, Abe K, Nakamura S, Suzuki D. Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Res Clin Pract. 2014;106(3):451–7.
-
(2014)
Diabetes Res Clin Pract
, vol.106
, Issue.3
, pp. 451-457
-
-
Toyoda, M.1
Yokoyama, H.2
Abe, K.3
Nakamura, S.4
Suzuki, D.5
-
62
-
-
84859867948
-
Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors
-
PID: 21856595
-
Varanasi A, Patel P, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors. Endocr Pract. 2012;18(2):140–5.
-
(2012)
Endocr Pract.
, vol.18
, Issue.2
, pp. 140-145
-
-
Varanasi, A.1
Patel, P.2
Makdissi, A.3
Dhindsa, S.4
Chaudhuri, A.5
Dandona, P.6
-
63
-
-
84884699311
-
Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study
-
COI: 1:CAS:528:DC%2BC3sXhs1Cmu7bI, PID: 22691169
-
Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440–3.
-
(2013)
J Eur Acad Dermatol Venereol
, vol.27
, Issue.11
, pp. 1440-1443
-
-
Ahern, T.1
Tobin, A.M.2
Corrigan, M.3
Hogan, A.4
Sweeney, C.5
Kirby, B.6
-
64
-
-
84898539437
-
Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study
-
COI: 1:CAS:528:DC%2BC2cXisFemurs%3D, PID: 24530118
-
Diaz-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. Diabetes Res Clin Pract. 2014;104(1):92–6.
-
(2014)
Diabetes Res Clin Pract
, vol.104
, Issue.1
, pp. 92-96
-
-
Diaz-Soto, G.1
de Luis, D.A.2
Conde-Vicente, R.3
Izaola-Jauregui, O.4
Ramos, C.5
Romero, E.6
-
65
-
-
84949228514
-
An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes
-
PID: 26637348
-
Gomez-Peralta F, Abreu C, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, et al. An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes. BMC Endocr Disord. 2015;15(1):78.
-
(2015)
BMC Endocr Disord.
, vol.15
, Issue.1
, pp. 78
-
-
Gomez-Peralta, F.1
Abreu, C.2
Castro, J.C.3
Alcarria, E.4
Cruz-Bravo, M.5
Garcia-Llorente, M.J.6
-
66
-
-
84928255405
-
Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus
-
PID: 25922845
-
Jinnouchi H, Sugiyama S, Yoshida A, Hieshima K, Kurinami N, Suzuki T, et al. Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Res. 2015;2015:706416.
-
(2015)
J Diabetes Res.
, vol.2015
, pp. 706416
-
-
Jinnouchi, H.1
Sugiyama, S.2
Yoshida, A.3
Hieshima, K.4
Kurinami, N.5
Suzuki, T.6
-
67
-
-
84995376436
-
Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India
-
COI: 1:CAS:528:DC%2BC2cXhtlajsrnI, PID: 24701434
-
Kaur P, Mishra SK, Mithal A, Saxena M, Makkar A, Sharma P. Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India. Indian J Endocrinol Metab. 2014;18(1):77–82.
-
(2014)
Indian J Endocrinol Metab.
, vol.18
, Issue.1
, pp. 77-82
-
-
Kaur, P.1
Mishra, S.K.2
Mithal, A.3
Saxena, M.4
Makkar, A.5
Sharma, P.6
-
68
-
-
80055042576
-
Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study
-
COI: 1:CAS:528:DC%2BC3MXhtlOns7zJ, PID: 21877924
-
Mori Y, Taniguchi Y, Sezaki K, Yokoyama J, Utsunomiya K. Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study. Diabetes Technol Ther. 2011;13(11):1139–44.
-
(2011)
Diabetes Technol Ther.
, vol.13
, Issue.11
, pp. 1139-1144
-
-
Mori, Y.1
Taniguchi, Y.2
Sezaki, K.3
Yokoyama, J.4
Utsunomiya, K.5
-
69
-
-
84888587857
-
A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice
-
PID: 23715814
-
Mulligan CM, Harper R, Harding J, McIlwaine W, Petruckevitch A, McLaughlin DM. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther. 2013;4(1):147–51.
-
(2013)
Diabetes Ther
, vol.4
, Issue.1
, pp. 147-151
-
-
Mulligan, C.M.1
Harper, R.2
Harding, J.3
McIlwaine, W.4
Petruckevitch, A.5
McLaughlin, D.M.6
-
70
-
-
84888438496
-
Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: a caution against inappropriate use in patients with reduced beta-cell function
-
COI: 1:CAS:528:DC%2BC3sXhvVOitL3J, PID: 24843713
-
Usui R, Yabe D, Kuwata H, Fujiwara S, Watanabe K, Hyo T, et al. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: a caution against inappropriate use in patients with reduced beta-cell function. J Diabetes Investig. 2013;4(6):585–94.
-
(2013)
J Diabetes Investig.
, vol.4
, Issue.6
, pp. 585-594
-
-
Usui, R.1
Yabe, D.2
Kuwata, H.3
Fujiwara, S.4
Watanabe, K.5
Hyo, T.6
-
71
-
-
84986190248
-
Albornos C, et al
-
Gomez-Peralta F, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, Albornos C, et al. Almodovar influence of liraglutide treatment in obstructive sleep apnea (OSA) in patients with obesity and diabetes mellitus type 2; 2013.
-
(2013)
Almodovar influence of liraglutide treatment in obstructive sleep apnea (OSA) in patients with obesity and diabetes mellitus type
, pp. 2
-
-
Gomez-Peralta, F.1
Castro, J.C.2
Alcarria, E.3
Cruz-Bravo, M.4
Garcia-Llorente, M.J.5
-
72
-
-
3442889435
-
Interpretation of observational studies
-
COI: 1:STN:280:DC%2BD2czltV2gtA%3D%3D, PID: 15253985
-
Jepsen P, Johnsen SP, Gillman MW, Sørensen HT. Interpretation of observational studies. Heart. 2004;90(8):956–60.
-
(2004)
Heart
, vol.90
, Issue.8
, pp. 956-960
-
-
Jepsen, P.1
Johnsen, S.P.2
Gillman, M.W.3
Sørensen, H.T.4
-
73
-
-
84986220143
-
Improved real-world glycemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes
-
Chicago, Illinois
-
DeKoven M, Lee W, Bouchard J, Edwy M, Langer J. Improved real-world glycemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. In: Presented at The American Diabetes Association (ADA) 73rd scientific sessions, June 21–25, Chicago, Illinois 2013.
-
(2013)
Presented at The American Diabetes Association (ADA) 73rd scientific sessions, June
, pp. 21-25
-
-
DeKoven, M.1
Lee, W.2
Bouchard, J.3
Edwy, M.4
Langer, J.5
-
74
-
-
84986229164
-
-
National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes in adults: management NICE guidelines [NG28] Published date: December 2015. Available from:. Accessed Feb 3, 2016
-
National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes in adults: management NICE guidelines [NG28] Published date: December 2015. Available from: http://www.nice.org.uk/guidance/ng28/chapter/1-Recommendations#hba1c-measurement-and-targets. Accessed Feb 3, 2016.
-
-
-
-
75
-
-
75549091263
-
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control
-
PID: 19858063
-
Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–59.
-
(2009)
Endocr Pract.
, vol.15
, Issue.6
, pp. 540-559
-
-
Rodbard, H.W.1
Jellinger, P.S.2
Davidson, J.A.3
Einhorn, D.4
Garber, A.J.5
Grunberger, G.6
-
76
-
-
84871995815
-
Standards of medical care in diabetes - 2013
-
American Diabetes Association. Standards of medical care in diabetes - 2013. Diabet Care. 2013;36(1):S11–66.
-
(2013)
Diabetes Care
, vol.36
, Issue.1
, pp. S11-S66
-
-
American Diabetes Association1
-
77
-
-
33646448307
-
Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss
-
COI: 1:CAS:528:DC%2BD28XjsVersb4%3D, PID: 16627822
-
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26(5):968–76.
-
(2006)
Arterioscler Thromb Vasc Biol
, vol.26
, Issue.5
, pp. 968-976
-
-
Poirier, P.1
Giles, T.D.2
Bray, G.A.3
Hong, Y.4
Stern, J.S.5
Pi-Sunyer, F.X.6
-
78
-
-
84986195386
-
The proportion of patients successfully treated with liraglutide—results from a post-hoc analysis of the EVIDENCE study
-
Boston, MA: USA
-
Gautier JF, Penfornis A, Charpentier G, Bouzidi A, Madani S, Martinez L, et al. The proportion of patients successfully treated with liraglutide—results from a post-hoc analysis of the EVIDENCE study. In: Presented at the 75th scientific sessions American Diabetes Association (ADA) 2015, June 5–9, 2015, Boston, MA, USA; 2015.
-
(2015)
Presented at the 75th scientific sessions American Diabetes Association (ADA) 2015, June 5–9
, pp. 2015
-
-
Gautier, J.F.1
Penfornis, A.2
Charpentier, G.3
Bouzidi, A.4
Madani, S.5
Martinez, L.6
-
79
-
-
84986239695
-
A retrospective assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide or sitagliptin from primary care centers in Sweden
-
Matsson P, Lind M, Johansson G, Svenningsson I, Jörgensen L, Ploug U, et al. A retrospective assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide or sitagliptin from primary care centers in Sweden. In: Presented at The SFD 7–8 May 2015; 2015.
-
(2015)
Presented at The SFD 7–8 May
, pp. 2015
-
-
Matsson, P.1
Lind, M.2
Johansson, G.3
Svenningsson, I.4
Jörgensen, L.5
Ploug, U.6
-
80
-
-
84986188104
-
Real life evidence of liraglutide effects supports efficacy shown in RCTs
-
Heymann A, Maor Y, Goldstein I, Todorava L, Schertz-Sternberg P, Karasik A. Real life evidence of liraglutide effects supports efficacy shown in RCTs. In: Presented at The World Diabetes Congress, Melbourne, 2–6 December 2013; 2013.
-
(2013)
Presented at The World Diabetes Congress, Melbourne, 2–6 December
, pp. 2013
-
-
Heymann, A.1
Maor, Y.2
Goldstein, I.3
Todorava, L.4
Schertz-Sternberg, P.5
Karasik, A.6
-
81
-
-
84986188105
-
Real life effects of liraglutide supports those shown in RCTs
-
Karasik A, Heymann A, Sternberg P, Leshno M, Todorova L, Goldshtein I, et al. Real life effects of liraglutide supports those shown in RCTs. In: Presented at The ISPOR 16th Annual European Congress, Dublin; 2–6th November 2013.
-
(2013)
Presented at The ISPOR 16th Annual European Congress, Dublin; 2–6th
-
-
Karasik, A.1
Heymann, A.2
Sternberg, P.3
Leshno, M.4
Todorova, L.5
Goldshtein, I.6
-
82
-
-
84986230820
-
The use of GLP-1 agonist liraglutide: adhereing to guidelines? Diabetic Medicine. 2014;31(Suppl 1):28–123. Abstract P154
-
Fatima J, Pearce S. The use of GLP-1 agonist liraglutide: adhereing to guidelines? Diabetic Medicine. 2014;31(Suppl 1):28–123. Abstract P154. Abstracts of the Diabetes UK Professional Conference, 5–7 March 2014.
-
(2014)
Abstracts of the Diabetes UK Professional Conference
, pp. 5-7
-
-
Fatima, J.1
Pearce, S.2
-
83
-
-
2342599057
-
One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2cXjslKiurc%3D, PID: 15111485
-
Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53(5):1187–94.
-
(2004)
Diabetes
, vol.53
, Issue.5
, pp. 1187-1194
-
-
Degn, K.B.1
Juhl, C.B.2
Sturis, J.3
Jakobsen, G.4
Brock, B.5
Chandramouli, V.6
-
84
-
-
23844463766
-
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
-
COI: 1:CAS:528:DC%2BD2MXnvVWksL0%3D, PID: 15886245
-
Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(8):4888–94.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, Issue.8
, pp. 4888-4894
-
-
Mari, A.1
Sallas, W.M.2
He, Y.L.3
Watson, C.4
Ligueros-Saylan, M.5
Dunning, B.E.6
-
85
-
-
77956076972
-
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents
-
COI: 1:CAS:528:DC%2BC3cXotFKhs7s%3D, PID: 20332351
-
Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33(6):1300–3.
-
(2010)
Diabetes Care
, vol.33
, Issue.6
, pp. 1300-1303
-
-
Buse, J.B.1
Sesti, G.2
Schmidt, W.E.3
Montanya, E.4
Chang, C.T.5
Xu, Y.6
-
86
-
-
84986228601
-
The efficacy of exenatide and liraglutide among South Asians in the Association of British Clinical Diabetologists nationwide audits
-
Thong KY, Sen Gupta P, Ryder REJ, ABCD nationwide exenatide and liraglutide audit contributors. The efficacy of exenatide and liraglutide among South Asians in the Association of British Clinical Diabetologists nationwide audits. In: Abstract book, 22nd World Diabetes Congress, IDF, Melbourne, Australia; 2–6 December 2013.
-
(2013)
Abstract book, 22nd World Diabetes Congress, IDF, Melbourne, Australia
, pp. 2-6
-
-
Thong, K.Y.1
Sen Gupta, P.2
Ryder, R.E.J.3
nationwide exenatide, A.B.C.D.4
-
87
-
-
84986230822
-
-
Victoza. Summary of Product Characteristics. Available from:. Accessed Feb 3, 2016
-
Victoza. Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf. Accessed Feb 3, 2016.
-
-
-
-
88
-
-
78851472141
-
Attaining a clinically relevant endpoint of HbA1c <7.0%, no weight gain and no hypoglycaemia with liraglutide as compared to other therapies in type 2 diabetes mellitus: a meta-analysis of the LEAD studies
-
Zinman B, Buse J, Falahati S, Moses A. Attaining a clinically relevant endpoint of HbA1c <7.0%, no weight gain and no hypoglycaemia with liraglutide as compared to other therapies in type 2 diabetes mellitus: a meta-analysis of the LEAD studies. Diabetologia. 2009;52(Suppl 1):S291.
-
(2009)
Diabetologia
, vol.52
, pp. S291
-
-
Zinman, B.1
Buse, J.2
Falahati, S.3
Moses, A.4
-
89
-
-
78851471129
-
Liraglutide—overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3MXjtFSgsbY%3D, PID: 21205109
-
Davies MJ, Kela R, Khunti K. Liraglutide—overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab. 2011;13(3):207–20.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.3
, pp. 207-220
-
-
Davies, M.J.1
Kela, R.2
Khunti, K.3
|